{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.7","upperLimit":"100","value":"97.5"},{"groupId":"OG001","lowerLimit":"89.8","upperLimit":"100","value":"97.5"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.7","upperLimit":"100","value":"97.5"},{"groupId":"OG001","lowerLimit":"89.7","upperLimit":"100","value":"97.5"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Achieving a donor derived ANC ≥ 500/mm3 for 3 consecutive laboratory values on different days. A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days and 365 days post transplant","title":"Cumulative Incidence of Neutrophil Recovery","type":"SECONDARY","unitOfMeasure":"percentage of participants"}